Cargando…
Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial
BACKGROUND: Advanced sarcoma is a group of heterogeneous disease with poor prognosis and poor efficacy of medical treatment. They represent a promising group of tumors to assess molecular-based therapy (MBT) strategy. PATIENTS AND METHODS: Genomic profiles of patients with advanced sarcoma included...
Autores principales: | Arnaud-Coffin, Patrick, Brahmi, Mehdi, Vanacker, Hélène, Eberst, Lauriane, Tredan, Olivier, Attignon, Valery, Pissaloux, Daniel, Sohier, Emilie, Cassier, Philippe, Garin, Gwenaelle, Pérol, David, Blay, Jean-Yves, Dufresne, Armelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509228/ https://www.ncbi.nlm.nih.gov/pubmed/32950930 http://dx.doi.org/10.1016/j.tranon.2020.100870 |
Ejemplares similares
-
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022) -
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program
por: Cassier, Philippe A., et al.
Publicado: (2021) -
TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021) -
Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma
por: Eberst, Lauriane, et al.
Publicado: (2020) -
Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)